Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
CA 2623540 A1 · Owner: Nara, Peter L. · Inventors: Goudsmit, Jaap; Garrity, Robert R.; Nara, Peter L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides an antibody specifically directed to an epitope that is , not immunodominant in an antigen of a pathogenic organism produced by , immunizing a , mammal with vaccine that can be administered to a mammal to cause immunoprotection in , the mammal against a pathogenic organism that has an immunodominant epitope. The , vaccine includes a modified form of the antigen in which the immunodominant epitope is , located. In this modified form the immunodominant epitope is immunodampened by any , of a number of techniques. Examples of immunodampening techniques include addition of , N-linked glycosylation sites change of the net charge of the epitope and , …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 19, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended August 19, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 19, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.